Aditxt (Aditxt) Insider Ownership : 77.21 % (As of Jun. 06, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aditxt Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aditxt's insider ownership is 77.21%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aditxt's Institutional Ownership is 0.87%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aditxt's Float Percentage Of Total Shares Outstanding is 98.82%.

Aditxt Insider Ownership Historical Data

The historical data trend for Aditxt's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aditxt Insider Ownership Chart

Aditxt Historical Data

The historical data trend for Aditxt can be seen below:

	2023-03-31	2023-04-30	2023-05-31	2023-06-30	2023-07-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Insider Ownership	29.93	24.85	19.02	19.01	17.25	77.21	77.21	77.21	77.21	77.21

Aditxt Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Aditxt (Aditxt) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aditxt Inc (NAS:ADTX) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

737 North Fifth Street, Suite 200, Richmond, VA, USA, 23219

Website

https://www.aditxt.com

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes a tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.

Executives

Charles Athle Nelson	director	11-F, BUILDING 12, SUNKING PLAZA, GAOJIAO ROAD, HANGZHOU, ZHEJIANG F4 311122
Bnp Paribas Securities Corp	10 percent owner	787 SEVENTH AVE, NEW YORK NY 10019
Matthew Shatzkes	officer: Chief Legal Officer and GC	737 N. FIFTH STREET, SUITE 200, RICHMOND VA 23219
Lauren Chung	director	1620 BEACON STREET, OXNARD CA 93033
Thomas J Farley	officer: PRINCIPAL ACCOUNTING OFFICER	2569 WYANDOTTE ST., SUITE 101, MOUNTAIN VIEW CA 94043
Jeffrey W. Runge	director	C/O PHARMATHENE, INC., ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
Rowena Albanna	officer: CHIEF OPERATING OFFICER	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Rosland Fisher Mcleod	director	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Pankovcin Corinne	officer: CHIEF FINANCIAL OFFICER	BUSINESS DEVELOPMENT CORP OF AMERICA, 405 PARK AVENUE, 14TH FLOOR, NEW YORK NY 10022
Laura E Anthony	director	LAURA ANTHONY, 120 S. OLIVE AVE, WEST PALM BEACH FL 33401
Namvar Kiaie	director	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Brian Michael Brady	director	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Amro A. Albanna	director, officer: CHIEF EXECUTIVE OFFICER	871 MARLBOROUGH AVENUE, SUITE 100, RIVERSIDE CA 92507
Shahrokh Shabahang	director, officer: CHIEF INNOVATION OFFICER	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354